



Guest Speakers:



Dr. Hanan Ghantous
USFDA/CDER



Dr. Nabil Al-Humadi
USFDA/CBER

Contact information

Yongbin.Zhang@fda.hhs.gov
(AACT)
Saif.Alharthy14@Stjohns.edu
(ATA)

Society of Toxicology AACT & ATA WEBINAR

Overview of Non-Clinical Safety Assessment for Antiviral Drugs and Vaccines Development

May 26, 2021
9:00 - 10:30 am (EDT)

An introductory overview of drug development and nonclinical safety assessment for drugs and biologics in general and specifically antivirals including COVID-19

Vaccines are one of the most cost-effective life-saving interventions in human history

Developing Drugs with direct antiviral activity, immunomodulatory activity, or other mechanisms of action

Please register and join us in this virtual event following the link below:

[AACT/ATA Webinar: Overview of Non-clinical Safety Assessment for Antiviral Drugs and Vaccines Development](#)